Andy Guinigundo, RN, CNP, ANP-BC, FAPO’s Post

Cancer Diagnostics Market 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞-https://lnkd.in/gyNZzbGp The global cancer diagnostics market in terms of revenue was estimated to be worth $17.2 billion in 2021 and is poised to reach $26.6 billion by 2026, growing at a CAGR of 11.5% from 2021 to 2026. Some of the major players operating in this market are GE Healthcare (US), Roche Diagnostics (Switzerland), and Becton, Dickinson and Company (US

Exciting News! 🚀 WestGene's WGc-043, a pioneering mRNA cancer vaccine, recently received historic FDA approval, marking a breakthrough in targeting Epstein-Barr virus-linked malignancies. This incredible therapy showcases remarkable efficacy and safety, promising new hope for cancer patients and setting a high bar for future oncological treatments. Dive into the full journey of innovation and clinical triumphs that led to this game-changing moment in cancer therapy by reading our article. 🌟 Make sure you reach out to us on [email protected] shall you wish to learn more, and hear how we could help you make the first step with your compound to find the perfect CRO for your trial. #CancerResearch #FDAApproval #mRNAtechnology #OncologyBreakthrough #HealthcareInnovation #WestGene *Whilst Life4Sciences has not been involved in any work on this trial, we sure know how to assist others in making the right business choices.

Cancer patients with the potential to end up on precision therapeutics fail to get there for two primary reasons: 1. More than 50% of the time, NCCN-recommended biomarker testing is not completed 2. In patients with actionable mutations, another 25% do not end up on matched precision therapeutic. OncoLens, used by more than 200 U.S. cancer centers, has a demonstrated track record of dramatically improving biomarker testing. Let's talk about #precisionmedicine #precisiononcology #biomarkers and how OncoLens can help in 2024!

A unique and interesting study in order to understand the challenges people with metastatic breast cancer face when learning about their biomarkers. One of the conclusion is that policy makers and their governments, healthcare professionals and their societies, patient advocates and their organisations, global health organisations, and pharmaceutical and diagnostic companies worldwide should work together to improve communication and understanding of biomarkers to patients with mBC. It is only through collaboration and concerted effort that change can be realised for the millions of people living with mBC today.

Annual Immuno-Oncology Summit 2024 https://lnkd.in/eTvH6Q_t #Biomarkers, #Cancer & #Oncology, #Cancer #immunotherapy, #CAR #Therapy, #Cell #Therapy, #Immuno-oncology, #IO #Targeting & #Discovery, #IO #Therapy, #Medical & #Pharma, #networking, #Oncology, #pipeline, #Preclinical #Research, #research

The surge in cancer instances highlights the crucial role radiotheranostics plays in transforming global healthcare.   Per The Business Research Company’s Radiotheranostics Global Market Report 2023, Cancer Research UK reported 18 million new cancer cases, with projections foreseeing a staggering 54.9% increase by 2040, reaching 28 million cases annually.   Understand how radiotheranostics medicines stand at the forefront, offering the promise of personalized treatment through diagnostic and therapeutic radionuclide probes.   Explore our comprehensive report for an in-depth analysis radiotheranostics market: https://lnkd.in/dJP5P3Vu . . . #radiotheranostics #radiopharmaceuticals #targetedradiotreatmen #cancerresearch #tbrc #thebusinessresearchcompany #marketresearch #marketintelligence

🔬 Join Quest Diagnostics' upcoming webinar on the evolving role of diagnostic labs in biomarker-driven oncology therapies. Dr. Yuri Fesko MD will delve into the transformative role of diagnostic labs in the rapidly advancing field of precision medicine. Attendees will learn how biomarkers like HER2 revolutionize cancer treatment with targeted therapies, streamline drug development, and enhance approval rates. The webinar will also cover the shift of diagnostic labs from service providers to proactive oncology partners, their role in clinical trials and companion diagnostics, and how precision medicine is reshaping oncology through real-world examples and case studies. 🔍 REGISTER HERE: https://buff.ly/4dwenpo #Cancer #PrecisionMedicine #Oncology #Biomarkers #ClinicalData #OncologyTrials #Diagnostics #TherapeuticAreas #OncologyDrugDevelopment

May is National Cancer Research Month, and as a cancer survivor, former clinician, and current pharmaceutical industry professional working in the cancer space, I understand the critical role of cancer research. Let's take a moment to recognize the researchers, clinicians, and patients who are dedicated to advancing our understanding of cancer and developing new treatments. Together, we can continue to make progress in the fight against this disease. #NationalCancerResearchMonth

🎥 Good news! Our latest webinar is now available to watch on demand! In it, you'll learn all about the latest advancements in organ-on-a-chip for cancer research and drug discovery. This webinar will not only cover capturing the tumor microenvironment (TME) in hepatocellular carcinoma in vitro but will explore how MIMETAS can help put therapeutic targets in immuno-oncology into patient context.   In this webinar, you will: - Gain unparalleled insights into replicating TME dynamics in vitro. - Engage in meaningful dialogue about TME complexities, focusing on angiogenesis, stroma, and immune responses. - Understand the impact of TME variables on the success of existing treatments. - Discover how partnership with MIMETAS can impact your oncology research, speeding up discovery and improving therapy prediction accuracy.   Watch the webinar here: https://lnkd.in/eBpNv8YE #CancerResearch #Immunooncology #OncologyResearch

🌟 Kognitic is proud to present our latest graphic: the top 20 companies spearheading Sarcoma and Bone Cancer clinical trials! 🌟 As July is World Sarcoma and Bone Cancer Awareness Month, we like to underscore the importance of continuous research and development in combating these challenging cancers. Our detailed ranking highlights the companies most active in Phase 2 and 3 trials, showcasing their commitment to advancing treatment options for sarcoma and bone cancer patients. Here's a glimpse of the top 5 leaders: 1. Amgen 2. Merck 3. Bristol-Myers Squibb (BMS) 4. Roche 5. Chia Tai Tianqing We're also excited to recognize Hansoh Pharma to the top 20, debuting with an 11 trials! Join us in celebrating these trailblazers in innovation and their relentless efforts to bring new treatments to patients faster and more effectively. Stay tuned for more updates and insights from Kognitic! #AIDrugLandscape #Sarcoma #BoneCancer #ClinicalTrials #Top20 #Kognitic #PharmaceuticalResearch #Innovation #AwarenessMonth #TPP